Naomi Verstegen

Naomi Verstegen

VU University of Amsterdam - Amsterdam / Netherlands
Medical and Health Sciences / Radiation Oncology
AD Scientific Index ID: 4703393
Vrije Universiteit Amsterdam
person_outline Naomi Verstegen's MOST POPULAR ARTICLES
1-) Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancerFJ Lagerwaard, NE Verstegen, CJA Haasbeek, BJ Slotman, MA Paul, ...International Journal of Radiation Oncology* Biology* Physics 83 (1), 348-353, 20123852012
2-) Stage I–II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a …NE Verstegen, JWA Oosterhuis, DA Palma, G Rodrigues, FJ Lagerwaard, ...Annals of oncology 24 (6), 1543-1548, 20133072013
3-) Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: comparison with a contemporaneous cohort with pathologically proven diseaseNE Verstegen, FJ Lagerwaard, CJA Haasbeek, BJ Slotman, S SenanRadiotherapy and Oncology 101 (2), 250-254, 20111362011
4-) Patterns of disease recurrence after SABR for early stage non–small-cell lung cancer: optimizing follow-up schedules for salvage therapyNE Verstegen, FJ Lagerwaard, SMS Hashemi, M Dahele, BJ Slotman, ...Journal of Thoracic Oncology 10 (8), 1195-1200, 2015832015
5-) Comparison of clinical outcome of stage I non-small cell lung cancer treated surgically or with stereotactic radiotherapy: results from propensity score analysisS Mokhles, N Verstegen, APWM Maat, Ö Birim, AJJC Bogers, ...Lung Cancer 87 (3), 283-289, 2015832015